Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02196324
Recruitment Status : Completed
First Posted : July 22, 2014
Results First Posted : February 2, 2021
Last Update Posted : May 20, 2021
Sponsor:
Information provided by (Responsible Party):
Vyne Therapeutics Inc.

Brief Summary:
The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.

Condition or disease Intervention/treatment Phase
Prurigo Nodularis Drug: serlopitant Drug: Placebo Phase 2

Detailed Description:
The sensation of itch is transmitted to the brain through the nervous system. Several chemicals are involved in transmitting this signal.This trial of VPD 737 is intended to treat this condition by blocking one of the chemicals involved in the transmission of the itch signal. This is an oral drug administered once daily It has been used in other trials and has shown to be safe at the doses used in this trial. The trial will involve once daily pills for 8 weeks. Subject will be asked to fill out questionnaires both electronically and on paper during the study period. Patients will also be monitored for safety and will have blood taken for testing and several points during the trial. Overall participation will last about 14 weeks

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 128 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis
Actual Study Start Date : July 9, 2014
Actual Primary Completion Date : May 27, 2016
Actual Study Completion Date : June 10, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: serlopitant 5 mg tablets
serlopitant 5 mg tablets
Drug: serlopitant
NK1 receptor antagonist
Other Name: VPD-737

Placebo Comparator: Placebo tablets
Placebo tablets
Drug: Placebo
Placebo




Primary Outcome Measures :
  1. Average Visual Analog Scale at Baseline [ Time Frame: At Baseline ]
    At study visits, participants recorded a mark for pruritus severity on a 10-cm horizontal line. This thermometer-type scale was marked with ratings of "no itch" (0 cm) and worst imaginable itch" (10 cm). Average Visual Analog Scale (VAS) (average itch over the past 24 hours) was recorded. Higher scores indicated worse outcome.

  2. Average Visual Analog Scale at Week 2 [ Time Frame: At Week 2 ]
    At study visits, participants recorded a mark for pruritus severity on a 10-cm horizontal line. This thermometer-type scale was marked with ratings of "no itch" (0 cm) and worst imaginable itch" (10 cm). Average VAS (average itch over the past 24 hours) was recorded. Higher scores indicated worse outcome.

  3. Average Visual Analog Scale at Week 4 [ Time Frame: At Week 4 ]
    At study visits, participants recorded a mark for pruritus severity on a 10-cm horizontal line. This thermometer-type scale was marked with ratings of "no itch" (0 cm) and worst imaginable itch" (10 cm). Average VAS (average itch over the past 24 hours) was recorded. Higher scores indicated worse outcome.

  4. Average Visual Analog Scale at Week 8 [ Time Frame: At Week 8 ]
    At study visits, participants recorded a mark for pruritus severity on a 10-cm horizontal line. This thermometer-type scale was marked with ratings of "no itch" (0 cm) and worst imaginable itch" (10 cm). Average VAS (average itch over the past 24 hours) was recorded. Higher scores indicated worse outcome.


Secondary Outcome Measures :
  1. Number of Participants With Improvement in Pruritus as Reported on Verbal Rating Scale (VRS) - Pruritus [ Time Frame: At Baseline and Week 8 ]
    At study visits, participants used the VRS to rate their skin sensations (pruritus, burning, and stinging) using a 5-point scale (0 = not present; 1 = mild present; 2 = moderately present; 3 = severely present; and 4 = very severely present). Higher scores indicated worse outcome.

  2. Number of Participants With Improvement in Burning as Reported on Verbal Rating Scale (VRS) - Burning [ Time Frame: At Baseline and Week 8 ]
    At study visits, participants used the VRS to rate their skin sensations (pruritus, burning, and stinging) using a 5-point scale (0 = not present; 1 = mild present; 2 = moderately present; 3 = severely present; and 4 = very severely present). Higher scores indicated worse outcome.

  3. Number of Participants With Improvement in Stinging as Reported on Verbal Rating Scale (VRS) - Stinging [ Time Frame: At Baseline and Week 8 ]
    At study visits, participants used the VRS to rate their skin sensations (pruritus, burning, and stinging) using a 5-point scale (0 = not present; 1 = mild present; 2 = moderately present; 3 = severely present; and 4 = very severely present). Higher scores indicated worse outcome.

  4. Worst Visual Analog Scale (VAS) [ Time Frame: At Baseline, Weeks 2, 4, and 8 ]
    At study visits, participants recorded a mark for pruritus severity on a 10-cm horizontal line. This thermometer-type scale was marked with ratings of "no itch" (0 cm) and worst imaginable itch" (10 cm). Worst VAS (worst itch over the past 24 hours) was recorded. Higher scores indicated worse outcome.

  5. Number of Participants With Improvement in Pruritus as Reported on Patient Global Assessment (PGA) [ Time Frame: At Weeks 2, 4, and 8 ]
    The PGA included a question: Did the pruritus improve during the treatment period (yes/no).

  6. Numeric Rating Scale (NRS) [ Time Frame: At Baseline, Weeks 2, 4, and 8 ]
    Numeric Rating Scale: Using the patient diary, participants rated the following using an 11-point NRS (0 = no itching; to 10 = worst itch imaginable): average itching over the past 24 hours (Average NRS). Higher scores indicated worse outcome.

  7. Dermatology Life Quality Index (DLQI) [ Time Frame: At Baseline, Weeks 2, 4, and 8 ]

    At each visit, participants completed a DLQI questionnaire. The DLQI is a validated questionnaire consisting of 10 questions relating to the degree to which the participant's skin condition affected his/her daily activities. The DLQI questionnaire is designed for use in adults, i.e. participants over the age of 16.

    The scoring of each question is as follows:

    Very much: scored 3, A lot: scored 2, A little: scored 1, Not at all: scored 0, Not relevant: scored 0, Question 7, 'prevented work or studying': scored 3.

    The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

    Interpreting the DLQI Scores:

    0 - 1: no effect at all on participant's life, 2 - 5: small effect on participant's life, 6 - 10: moderate effect on participant's life, 11 - 20: very large effect on participant's life, 21 - 30: extremely large effect on participant's life.


  8. Pruritus-specific Quality of Life (ItchyQoL) [ Time Frame: At Baseline, Weeks 2, 4, and 8 ]

    At each visit, participants completed an ItchyQoL questionnaire. The ItchyQoL is a validated questionnaire consisting of 22 questions based on the concerns and issues pertinent to participants with pruritus.

    Items should be scored for the following answers:

    Never: 1, Rarely: 2, Sometimes: 3, Often: 4, All the time:5. Higher scores indicated worse outcome. Total Score is obtained by calculating the unweighted mean of all ItchyQoL questions.


  9. Patient Benefit Index, Version for Patients With Pruritus (PBI-P) [ Time Frame: At Week 8 / End of Treatment ]
    At Visits 2 and 5 (or Early termination) only, participants completed the standardized and validated PBI-P questionnaire. Prior to treatment, the first page of the questionnaire, the Patient Needs Questionnaire (PNQ), was administered to determine how different benefits of therapy were relevant for the individual participant. After treatment, using the Patient Benefit Questionnaire (PBQ), participants were asked to evaluate the extent to which the benefits they indicated were important to them were, in fact, realized. From all the items taken together, a weighted total benefit value was calculated, which represented the patient relevant therapy benefits. The mean score greater than 1 is considered to represent a clinically relevant improvement. The items are rated on a 5-point scale with values from 0 (not at all) to 4 (very), allowing for "does/did not apply to me" = 5; and missing value = -9. Higher scores indicated better outcome.

  10. Number of Participants With Improvement in PN Lesions as Reported on Investigator Global Assessment (IGA) [ Time Frame: At Week 8 ]
    Using the IGA, physicians rated change in PN lesions (if any) from +5 ("markedly improved") to -5 ("markedly worse"). Higher scores indicated better outcome.

  11. Number of Participants With Improvement on Prurigo Activity Score (PAS) [ Time Frame: At Day 1 and Week 8 ]

    Using the PAS, physicians described, localized, counted, and measured PN lesions.

    One of the 7 items was:

    Activity Stage (Stage 0-4: 0 = 0%, 1 = 1-25%, 2 = 26-50%, 3 = 51-75%, 4 = > 75%)

    a. Prurigo lesions with excoriations/crusts

    Participants with PAS activity stage (prurigo lesions with excoriations/crusts) is presented in the below table.


  12. Participants With Rescue Medication Usage [ Time Frame: Pre-treatment, upto 8 Weeks ]
    Rescue medications included cetirizine hydrochloride, desloratadine, levocetirizine, and loratadine.

  13. Number of Participants With Adverse Events (AEs) [ Time Frame: From the time of informed consent (Screening) until the last study visit (follow-up phone call, Week 10) ]
    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE (also referred to as an adverse experience) could be any unfavorable and unintended sign (eg, an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, without any judgment about causality.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects meeting all of the following criteria will be eligible for study entry:

    1. Males or females who are at least 18 years and no more than 80 years of age at Screening.
    2. Must have PN (defined as the presence of pruritic nodules due to chronic pruritus,) of more than 6 weeks duration despite treatment with current therapies such as antihistamines or corticosteroids ("treatment resistant" PN).
    3. Must have PN lesions on both arms, both legs, and/or the trunk (ie, the lesions must not be localized).
    4. Must have a VAS pruritus score of 70 or greater within 72 hours of Baseline.
    5. Males, non-fecund females (ie, surgically sterilized, if procedure was done 12 months before screening or subject is postmenopausal, without menses for 12 months before screening), or females of childbearing potential using an acceptable method of birth control for a period of 35 days before the first dosing, and all females must have a negative pregnancy test at the screening and baseline visits:

      Note 1: Acceptable methods of birth control include any one of the following:

      abstinence, vasectomized sexual partner, hormonal methods (ie, birth-control pill, hormonal IUD, Depo-Provera, implants, patch, intravaginal device [NuvaRing]), intrauterine device (IUD [copper banded coils]), diaphragm, cervical cap, or condom with spermicidal jelly or foam. Subjects using oral contraceptives must also use a reliable backup method of birth control during the study and until the first menses after the last dose of study medication or for 14 days menses after the last dose of study medication.

    6. Willing and able to understand and provide written informed consent.
    7. Willing and able to comply with study requirements and restrictions including the discontinuation of all current therapies for pruritus.
    8. Subjects must be in good health as determined by medical history, physical examination, and results of Electro Cardio Gram (ECG) and clinical laboratory tests (including urinalysis).
    9. Agreeing to confidential use and storage of all data and use of all anonymized data for publication including scientific publication.

Exclusion Criteria:

  • Subjects not eligible for the study are those who:
  • Have chronic pruritus due conditions other than PN, such as the following conditions:
  • Lichen simplex chronicus
  • Lichen amyloidosus
  • Localized pruritus (e.g., only one arm affected)
  • Neuropathic and psychogenic pruritus (notalgia paresthetica, brachioradial pruritus, somatoform prurigo, dilusional parasitosis, depression associated prurigo)
  • Active dermatoses needing immediate therapy such as atopic dermatitis (without PN) or bullous pemphigoid;
  • Have a history of use (within the specified time periods) of the medications listed below. Prior to randomization, a subject who used any of these medications must undergo a washout period equal to the length of the interval specified below (eg, 2 weeks for antihistamines, 4 weeks for naltrexone, and 4 weeks for cyclosporine A).
  • Topical or systemic antihistamines, (used ≤2 weeks prior to the baseline visit) [loratindine, or cetirizine may act as rescue medication during treatment];
  • Topical calcineurin inhibitors, topical capsaicin, menthol, camphor, polidocanol, topical antibiotics, antiseptic baths and cleansing lotions (used ≤2 weeks prior to the baseline visit);
  • Topical steroids (used ≤2 weeks prior to the baseline visit);
  • Naltrexone, paroxetine, fluvoxamine, amitriptyline, gabapentin, pregabalin, or UVtherapy (prescribed for the pruritus treatment) (used ≤4 weeks prior to the baseline visit);
  • Systemic steroids (used ≤4 weeks prior to the baseline visit);
  • Cyclosporine A and other immunosuppressants (used ≤4 weeks prior to the baseline visit).
  • Have any medical condition or disability that would interfere with the assessment of safety or efficacy in this trial or would compromise the ability of the subject to undergo study procedures or to give informed consent.
  • Have any chronic or acute medical condition that, in the opinion of the investigator, might interfere with the study results or place the subject at undue risk.
  • Have a history of sensitivity to any components of the study material.
  • Are females of childbearing potential who are unwilling to use adequate contraception or who are breast feeding.
  • Have chronic renal disease, ie, serum creatinine greater than 2.4 mg/dL.
  • Have aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal. Subjects with hepatitis B or C who have normal liver function may be enrolled.
  • Have a current malignancy (such as Hodgkin's lymphoma, B or T cell lymphoma, or myeloma) or blood cell dyscrasia (eg, polycythemia or myelofibrosis) that might lead to systemic chronic pruritus.
  • Subjects with untreated hyperthyroidism.
  • Have pruritus of psychiatric etiology (eg, delusions of parasitosis, obsessive compulsive disorder, or major depression) or neuropathic etiology (eg, due to shingles, spinal cord injury or with neurologic deficit).
  • Have pruritus due to urticaria, drug allergy, or infection (such as pityriasis rosea or tinea or active human immunodeficiency virus [HIV]). Note: Subjects with HIV who have undetectable viral load, CD 4 counts >200 cells/cc, and stable retroviral therapy may enroll.
  • Are on medications known to cause pruritus (ie, Erbitux®, opioids, cocaine, amphetamines, and angiotensin converting enzyme [ACE] inhibitors) and are suspected of having drug-induced pruritus.
  • Have taken investigational medications within 30 days prior to Screening.
  • Are currently participating in any other clinical study.
  • Have a history (within the previous 4 weeks) of use of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRIS), monoamine oxidase (MAO) inhibitors, opioids, immunemodulators (e.g. azathioprine, methotrexate, mycophenolate mofetil, cyclosporine A, antibodies), or neuroactive medications (e.g. pregabalin, gabapentin).
  • Have a history (within the previous 4 weeks) of use of sedatives or tranquilizers.

Subjects must undergo an appropriate washout period from any sedatives or tranquilizers before enrolling in the study.

  • Are currently treated with strong CYP3A4 inhibitors (e.g. conazole, ketoconazole, fluconazole, itraconazole, voroconazole etc. or erythromycin). The co-administration of moderate CYP3A4 inhibitors to VPD-737 may be allowed with investigator agreement and appropriate safety monitoring.
  • Received ultraviolet B (UVB) or psoralen + ultraviolet A (PUVA) treatment within 30 days prior to Screening.
  • Within the past 12 months, have expressed suicidal ideation with some intent to act.
  • Started or changed creams, or emollients including over-the-counter (OTC) preparations or bath oil treatment for relief of pruritus within 2 weeks prior to Screening.
  • Have any social or medical condition (eg, alcoholism, drug dependency, psychotic state) that, in the investigator's opinion, might interfere with the subject's ability to comply with the requirements of the protocol.
  • Are employees of the study site or of the Sponsor's company.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02196324


Locations
Layout table for location information
Germany
Study Site 07
Berlin-Mitte, Germany, 10117
Study Site 08
Bonn, Germany, 53127
Study Site 06
Dresden, Germany, 01307
Study Site 12
Dusseldorf, Germany, 40225
Study Site 02
Frankfurt, Germany, 60590
Study Site 09
Hamburg, Germany, 20246
Study Site 05
Heidelberg, Germany, 69120
Study Site 03
Kiel, Germany, 24105
Study Site 11
Leipzig, Germany, 04103
Study Site 04
Lubeck, Germany, 23538
Study Site 14
Mainz, Germany, 55101
Study Site 01
Muenster, Germany, 48149
Study Site 16
München, Germany, 80337
Study Site 15
Selters, Germany, 56242
Study Site 10
Tübingen, Germany, 72076
Sponsors and Collaborators
Vyne Therapeutics Inc.
Investigators
Layout table for investigator information
Principal Investigator: Sonja Staender, MD University of Muenster, Germany
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Vyne Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT02196324    
Other Study ID Numbers: TCP-102
First Posted: July 22, 2014    Key Record Dates
Results First Posted: February 2, 2021
Last Update Posted: May 20, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Vyne Therapeutics Inc.:
Prurigo Nodularis
Atopic Dermatitis
Lichen-simplex chronicus
Additional relevant MeSH terms:
Layout table for MeSH terms
Prurigo
Neurodermatitis
Skin Diseases
Dermatitis
Skin Diseases, Eczematous
Serlopitant
Neurokinin-1 Receptor Antagonists
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs